Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study

Table 2

Rates of resistance (%) of the isolates to antimicrobial agents.

Antimicrobial	Acinetobacter baumannii		Klebsiella pneumoniae		Escherichia coli		Stenotrophomonas maltophilia
	Ampicillin	0	100				100
Piperacillin-tazobactam	9.5	76.2	0	80.0	33.3	66.7	0	100
Ceftriaxone	0	100	0	100	0	100
Ceftazidime	4.8	81.0	20.0	80.0	0	100	0	100
Cefepime	19.0	76.2	20	60.0	33.3	66.7
Cefoperazone-Sulbactam	14.3	476.2	0	100	33.3	66.7	0	100
Aztreonam	28.6	71.4	0	80.0	0	66.7	0	100
Imipenem	23.8	66.7	25.0	75.0	0	100	0	100
Meropenem	28.6	61.9	0	100	33.3	66.7	0	100
Levofloxacin	33.3	57.1	20	60.0	0	100
Minocycline	28.6	52.4	20	60	0	66.7
Gentamycin	14.3	47.6	0	50	0	100	50	50
SMZ-TMP	0	47.6	0	80			0	50
	4.8	0	0	0	0	0	0	0

: tigecycline, : intermediate, and : resistance.